|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1200 - 0.1200|
|52 Week Range||0.0377 - 0.5685|
|Beta (5Y Monthly)||3.01|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Telo Genomics Corp. (TELO.V) (the “Company” or “TELO”), is pleased to announce that it has signed a collaboration agreement with Mayo Clinic in Minnesota to conduct clinical studies to evaluate and validate the utility of the Company’s proprietary telomere analytics as a prognostic solution for Multiple Myeloma. The collaboration studies will be led by Dr. Shaji Kumar, MD, and were designed to include two retrospective phases with the potential of a third prospective phase. For each phase, TELO’s analytics will be employed to: 1) predict the progression of multiple myeloma precursors to full stage multiple myeloma, and 2) predict patient responses to first-line therapy at the point of diagnosis.
TORONTO, Nov. 28, 2019 -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) announces that it has granted incentive stock options to various directors, officers,.